The study, published in the Journal of Molecular Medicine, was led by Alejandro Silva-Palacios, Alejandra María Zúñiga-Muñoz, and Cecilia Zazueta of the National Institute of Cardiology Ignacio Chávez in Mexico City, together with collaborators at the National Autonomous University of Mexico and Tecnológico de Monterrey. The researchers set out to test whether cannabidiol, commonly abbreviated as CBD, could protect the heart in an animal model that closely mimics the human condition. They induced HFpEF in mice by combining a high-fat diet with L-NAME, a compound that inhibits nitric oxide synthesis and drives the nitrosative stress considered central to the disease. Over eight weeks, the animals developed the hallmark features of HFpEF: cardiac fibrosis, diastolic dysfunction, and systemic metabolic and inflammatory disturbances. CBD was then administered subcutaneously every three days, a dosing interval chosen to maintain sustained exposure to the compound.

The results were nuanced but striking. CBD did not shrink the enlarged, hypertrophied hearts of the diseased animals; cardiac hypertrophy persisted despite treatment. However, the compound produced meaningful improvements where they mattered most for HFpEF patients. Treated animals showed reduced cardiac fibrosis, the stiffening scar tissue that prevents the heart muscle from relaxing, and their diastolic function improved measurably. The researchers assessed hemodynamic performance using invasive pressure-volume loop analysis, the gold standard for evaluating how the ventricle fills and ejects blood, and complemented these measurements with histological examination and markers of oxidative stress. The improvement in filling dynamics, rather than pumping strength, is precisely the kind of benefit that HFpEF patients need, since their hearts fail not because they pump too weakly but because they cannot relax enough to refill.

To understand how CBD achieved these effects, the team turned their attention to cellular senescence, the state in which cells stop dividing but refuse to die, instead lingering in tissues and secreting a toxic cocktail of inflammatory molecules. This senescence-associated secretory phenotype, or SASP, has emerged as a key driver of age-related diseases, and growing evidence links it to heart failure. In the HFpEF mice, senescent cells had accumulated in the heart, and circulating cytokine levels were elevated, consistent with a body-wide SASP-driven inflammatory state. CBD treatment markedly reduced the accumulation of these senescent cells and lowered systemic cytokine levels. The finding suggests that CBD may act as a partial senotherapeutic, clearing or calming the aged cells that fuel chronic inflammation in the failing heart.

The second major target was the NLRP3 inflammasome, a molecular machine inside immune and cardiac cells that, when activated, triggers caspase-1 and the release of potent proinflammatory cytokines such as interleukin-1 beta. NLRP3 activation has been implicated in cardiac remodeling, pulmonary artery changes, and general inflammation in HFpEF, and pharmacological inhibitors of this inflammasome have already shown benefit in mouse models of the disease. In the current study, CBD suppressed the NLRP3-mediated proinflammatory state, adding to a growing body of evidence that the compound can dampen inflammasome signaling. Previous work had shown that CBD inhibits NLRP3 activation in human monocytes through modulation of the P2X7 receptor, and that cannabinoids can attenuate cytokine storms driven by inflammasome pathways. The new findings extend this anti-inflammatory repertoire into the HFpEF setting.

Perhaps the most novel contribution of the study lies in its third focus: the mitochondria-endoplasmic reticulum contact sites, abbreviated MERCSs. These are microscopic junctions where the membranes of mitochondria, the cell’s power plants, and the endoplasmic reticulum, its protein-folding and calcium-storage factory, come into close apposition. At these contact points, the two organelles exchange calcium, lipids, and stress signals, coordinating everything from energy metabolism to cell death decisions. When MERCSs become excessive or disorganized, calcium overload and mitochondrial destabilization can activate the NLRP3 inflammasome, linking organelle architecture directly to inflammation. Using transmission electron microscopy, immunofluorescence, and RT-qPCR, the researchers found that in HFpEF the integrity of these contact sites was compromised, and that CBD treatment preserved inter-organelle distance and MERCSs structure.

This is the first demonstration, according to the authors, that CBD modulates MERCSs communication to regulate senescence and inflammation in HFpEF. The finding ties together threads that had previously run in parallel. Earlier work from the same group had shown that senotherapy in obese rats could act through a MERCSs/Nrf2 interaction, and other studies had established that disrupted sarcoplasmic reticulum-mitochondrial contacts underlie contractile dysfunction in atrial fibrillation, while enhanced tethering can trigger adaptive cardiac remodeling. In diabetes, hyperglycemia-driven promotion of mitochondria-associated endoplasmic reticulum membranes contributes to cardiomyopathy, and in aged hearts, defective calcium exchange between these organelles impairs function. By preserving the geometry of these junctions, CBD appears to prevent the calcium mishandling and mitochondrial stress that ignite inflammasome activation, thereby interrupting a vicious cycle in which organelle damage feeds inflammation, which in turn accelerates cellular aging.

The implications extend beyond the laboratory. HFpEF accounts for roughly half of all heart failure cases, and its burden is growing with the obesity and diabetes epidemics. Current treatment options remain limited, with recent trials of sodium-glucose cotransporter-2 inhibitors offering only partial benefit, and one such agent, empagliflozin, has been shown to protect against HFpEF partly by inhibiting a senescence-associated signaling axis. Pharmacological clearance of senescent cells has independently been shown to reduce inflammation, endothelial damage, and cardiac fibrosis in HFpEF models. The convergence of these findings suggests that targeting the biology of aging itself—senescent cells, their secretory products, and the organelle networks that control cellular stress—may be a viable therapeutic strategy for a disease that has defied conventional approaches.

CBD brings its own compelling profile to this strategy. Unlike tetrahydrocannabinol, it does not produce intoxication, and it has already been approved for certain forms of epilepsy, giving clinicians experience with its safety profile. Prior animal studies have shown that CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory signaling in diabetic cardiomyopathy, prevents heart failure dysfunction through preservation of mitochondrial function and calcium handling, and promotes cardiomyocyte proliferation after myocardial infarction. A clinical trial, the ARCHER study, is currently evaluating CBD’s impact on myocardial recovery in patients with acute myocarditis. The new HFpEF findings add another potential indication to this expanding list, though the authors caution that the signaling pathways connecting MERCSs preservation to reduced senescence and inflammation still need to be fully characterized.

Important questions remain before CBD can be considered a treatment for HFpEF. The study was conducted in mice, and the dose, route, and timing of administration would need careful translation to humans. The failure to reduce hypertrophy suggests that CBD addresses some but not all of the disease’s pathological drivers, and it is unclear whether starting treatment earlier or later would change the outcome. Nevertheless, by identifying premature senescence, NLRP3-mediated inflammation, and MERCSs integrity as linked, druggable targets in HFpEF, the Mexican team has offered both a mechanistic explanation for CBD’s cardioprotective effects and a roadmap for the next generation of experiments. For a disease that affects millions and has resisted nearly every therapeutic attempt, the idea that a well-tolerated plant-derived compound might restore youthful communication between a cell’s organelles and quiet the inflammatory noise of aging tissue is a prospect worth watching closely.

Subject of Research: The cardioprotective effects of cannabidiol in heart failure with preserved ejection fraction through modulation of cellular senescence, NLRP3 inflammation, and mitochondria-endoplasmic reticulum contact sites.

Article Title: Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF

Article References: Silva-Palacios, A., Zúñiga-Muñoz, A. M., Soria-Castro, E., Álvarez-León, E., García-Niño, W. R., Navarrete-Anastasio, G., Raza, D., Aparicio-Trejo, O. E., Ramírez-Carreto, R. J., Salas-Venegas, V., Chavarría, A., Maldonado-Ruíz, R. A., Alves-Figueiredo, H., García-Rivas, G., & Zazueta, C. (2026). Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of Molecular Medicine, 104(1), Article 109. https://doi.org/10.1007/s00109-026-02715-4

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02715-4

Keywords: heart failure, HFpEF, cannabidiol, cellular senescence, SASP, NLRP3 inflammasome, MERCSs, mitochondria, endoplasmic reticulum, cardiac fibrosis, diastolic dysfunction, inflammation

CINP is a major dose-limiting toxicity of some of the most widely used chemotherapy classes, including platinum drugs such as oxaliplatin and cisplatin, taxanes like paclitaxel, and vinca alkaloids. Estimates suggest that between 30 and 60 percent of patients receiving certain regimens develop the condition. Clinically, it presents as spontaneous and evoked persistent pain, frequently manifesting as mechanical and thermal allodynia—pain triggered by normally harmless stimuli such as light touch or mild warmth. But the damage does not stop at pain. Patients often experience additional sensory disturbances, motor dysfunction, cognitive impairment, and affective disorders, all of which severely compromise quality of life and, in some cases, force oncologists to reduce or discontinue life-prolonging treatment.

The therapeutic landscape is bleak. According to the review, current preventive measures are essentially lacking, and the treatments that do exist are largely palliative, managing symptoms without addressing the underlying neurobiological mechanisms. Standard analgesics, including some antidepressants and anticonvulsants borrowed from other neuropathic pain conditions, offer incomplete relief for many patients. This gap has driven researchers to look for targets that act on the biology of the damaged nerves themselves—and the endocannabinoid system has emerged as one of the most intriguing candidates.

The endocannabinoid system is the body’s endogenous modulator of pain processing, active under both physiological and pathological conditions. It comprises two principal endogenous ligands, anandamide and 2-arachidonoylglycerol (2-AG), the enzymes that synthesize and metabolize them—including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL), diacylglycerol lipases (DAGL), and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD)—fatty acid-binding proteins and membrane transporters that shuttle the ligands, and two main receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2). CB1 receptors are densely expressed at central and peripheral sites along the pain pathway, while CB2 receptors are prominent on immune cells and become upregulated in injury states. Together, these components exert multifaceted regulatory effects at the periphery, in the spinal cord, and in the brain.

What makes the endocannabinoid system particularly interesting in the context of CINP is that experimental models show dynamic changes in its components after chemotherapy exposure. Rather than being a static bystander, endogenous cannabinoid signaling appears to become dysregulated as neuropathy develops, suggesting that restoring or enhancing this signaling could be therapeutically useful. Indeed, the review documents that direct or indirect modulation of cannabinoid receptors has been shown to both prevent and mitigate behavioral indicators of pain in CINP models. Strategies include direct agonists such as arachidonyl-2′-chloroethylamide (ACEA), inhibitors of the enzymes that break down anandamide and 2-AG, positive allosteric modulators that fine-tune receptor activity, and interventions targeting the endocannabinoid membrane transporter. Indirect approaches are especially attractive because they amplify endocannabinoid signaling only where and when it is naturally produced, potentially reducing the central side effects—such as psychoactivity—that limit direct CB1 agonism.

Beyond the endocannabinoid system itself, preclinical studies have explored the analgesic and neuroprotective properties of phytocannabinoids derived from the cannabis plant, primarily Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). The evidence indicates that both compounds, administered alone or in combination, can alleviate neuropathic pain in CINP models. THC acts as a partial agonist at CB1 and CB2 receptors, while CBD has a more complex pharmacology, interacting with transient receptor potential (TRP) channels and other targets, and modulating endocannabinoid tone indirectly. The combination of the two has drawn particular interest because CBD may temper THC’s psychoactive effects while contributing its own analgesic and anti-inflammatory actions. Animal studies of paclitaxel-, oxaliplatin-, and cisplatin-induced neuropathy have reported reductions in mechanical and thermal hypersensitivity following cannabinoid treatment, in some cases with evidence of neuroprotection of sensory neurons in the dorsal root ganglia.

Yet the translation from bench to bedside has been disappointing. The review finds that clinical studies in patients with CINP have reported only modest or inconsistent benefits. Several factors may explain this translational gap. Preclinical models typically use fixed doses and formulations in young, otherwise healthy animals, whereas clinical trials must contend with heterogeneous patient populations, variable chemotherapy regimens, differing stages of neuropathy, and a wide range of cannabinoid products with uncertain composition and bioavailability. Dosing regimens that work in rodents may not map onto tolerable doses in humans, where psychoactive effects of THC and drug interactions with ongoing cancer therapy complicate escalation. The review underscores the need for rigorous preclinical characterization of phytocannabinoid formulations and dosing regimens precisely to bridge this gap—ensuring that the compounds, ratios, doses, and timing tested in animals are those most likely to succeed in the clinic.

The authors also emphasize the broader burden of CINP as a rationale for continued investment. Because the condition can compromise chemotherapy dosing, it affects not only quality of life but potentially oncological outcomes. A therapy that could prevent the onset of neuropathy—or reverse it once established—without interfering with chemotherapy’s anti-tumor efficacy would represent a significant advance. The endocannabinoid system’s position at the interface of neuronal and immune signaling makes it a plausible candidate for such dual protective and analgesic roles, and its modulation offers multiple pharmacological entry points, from enzyme inhibitors to receptor subtype-selective ligands that avoid central psychoactive effects by targeting peripheral CB1 or CB2 receptors.

In synthesizing the field, Soriano and Coronel aim to integrate current knowledge, highlight key translational gaps, and identify priorities for future research. Their critical appraisal makes clear that the story of cannabinoids and chemotherapy-induced neuropathic pain is neither one of simple promise nor of failure. The endocannabinoid system is genuinely dysregulated in experimental CINP, and manipulating it genuinely relieves pain-like behavior in animals. But the leap to effective, safe, and reproducible treatments for patients has not yet been made, and the clinical data that exist are too limited to support confident recommendations. The path forward, the review suggests, lies in better-controlled preclinical studies that mirror clinical conditions, carefully designed formulations and dosing strategies, and clinical trials rigorous enough to determine once and for all whether cannabinoid-based therapies can deliver on the promise that two decades of animal research has generated.

For now, patients and clinicians are left in an uncomfortable middle ground: a biological system with strong mechanistic credentials, a family of compounds with demonstrated preclinical efficacy, and a clinical evidence base that has not kept pace. As cannabis-derived medicines continue to attract public and scientific attention, this review serves as a sober reminder that enthusiasm must be matched by methodological rigor—and that the gap between what works in a mouse and what helps a patient remains one of the most important challenges in cannabinoid pain research.

Subject of Research: The role of the endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain, from preclinical promise to limited clinical evidence.

Article Title: The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence

Article References: Soriano, D., & Coronel, M. F. (2026). The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05585-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05585-y

Keywords: chemotherapy-induced neuropathic pain, endocannabinoid system, cannabinoid receptors, CB1, CB2, THC, cannabidiol, neuropathic pain, phytocannabinoids, allodynia, pain management, cancer survivors